Onclive Team

Roswell Park's Dr. Pawel Kalinski to Lead $14.5M NCI-Funded Immunotherapy Effort

March 31st 2020

A team led by Pawel Kalinski, MD, PhD, of Roswell Park Comprehensive Cancer Center has earned a five-year, $14.54 million award from the National Cancer Institute to expand a promising immunotherapy platform.

Expert Perspectives in the Evolving ALK+ NSCLC Paradigm

March 24th 2020

In a wide-ranging discussion, Alexander Drilon, MD; Julia Rotow, MD; Thomas E. Stinchcombe, MD; and Ashish Saxena, MD, PhD, provide expert insight on developments in ALK-positive non–small cell lung cancer.

OncLive and The Ruesch Center for the Cure of Gastrointestinal Cancers Names the 2020 Honorees of the Luminary Awards in GI Cancers

March 24th 2020

OncLive, in conjunction with The Ruesch Center for the Cure of Gastrointestinal Cancers, honored five individuals with a 2020 Luminary Award in Gastrointestinal Cancers for their commitment to the gastrointestinal cancer community.

BTK Inhibitors Transform Treatment in CLL, MCL, and Waldenstrom Macroglobulinemia

March 23rd 2020

Constantine S. Tam, MD, MBBS, highlights the impact of BTK inhibitors in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia.

Updates in the ALK-Positive NSCLC Paradigm

March 23rd 2020

Advanced, recurrent, and metastatic NSCLC is often associated with poor prognosis, and treatment is aimed to extend survival and provide symptom management.

An Expert Assessment of Available BTK Inhibitors Within the CLL Treatment Spectrum

March 20th 2020

Brad S. Kahl, MD, discusses the use of BTK inhibitors, which have revolutionized the treatment paradigm in chronic lymphocytic leukemia.

Exploring the Role of BTK Inhibitors in B-Cell Lymphomas

March 20th 2020

During an OncLive® Scientific Interchange, community and academic oncologists review the current treatment landscape and evaluate therapeutic strategies involving BTK inhibitors in B-cell lymphomas.

Experts Weigh In on Top Abstracts From Genitourinary Cancers Symposium

March 18th 2020

How to best pair immune checkpoint inhibitors with other agents known to have efficacy in genitourinary cancers was a key avenue of inquiry of many of the studies presented at the 2020 Genitourinary Cancers Symposium.

Randall A. Oyer, MD, Becomes President of the Association of Community Cancer Centers

March 11th 2020

Randall A. Oyer, MD, was named the Association of Community Cancer Centers (ACCC) President for 2020-2021 at the ACCC 46th Annual Meeting & Cancer Center Business Summit held March 4-6 in Washington, D.C.

From Scorpion to Immunotherapy: City of Hope Scientists Repurpose Nature's Toxin for First-Of-Its Kind CAR T Cell Therapy to Treat Brain Tumors

March 5th 2020

City of Hope scientists have developed and tested the first CAR T-cell therapy using chlorotoxin, a component of scorpion venom, to direct T cells to target brain tumor cells.

Johnathan R. Whetstine Awarded Lung Cancer Discovery Award

March 3rd 2020

International Association for the Study of Lung Cancer Names Research Award after Dr. Fred R. Hirsch

March 2nd 2020

The International Association for the Study of Lung Cancer (IASLC) announced it is naming the Translational Research Lectureship Award after longtime member and former IASLC CEO, Fred R. Hirsch, MD, PhD, Executive Director of the Center for Thoracic Oncology and Associate Director of Biomarker Discovery at The Tisch Cancer Institute at Mount Sinai and the Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai.

Next Chapter Begins With CAR T-Cell Therapy in Myeloma

March 1st 2020

Noopur Raje, MD, discusses the investigational CAR T-cell therapies and strategies in the multiple myeloma pipeline.

Kunz named Leader of Gastrointestinal Cancers Program at Smilow Cancer Hospital and Yale Cancer Center

February 19th 2020

Nivolumab Plus Sitravatinib Highly Active in ccRCC

February 17th 2020

Combining nivolumab (Opdivo) with sitravatinib induced a confirmed objective response rate of 39% and a 92% clinical benefit rate in patients with advanced clear cell renal cell carcinoma.

Novel Agent MK-6482 Shows Promise in Renal Cell Carcinoma

February 16th 2020

The oral hypoxia-inducible factor-2α inhibitor MK-6482 induced a partial response rate of 24% and a disease control rate of 80% in patients with advanced clear cell renal cell carcinoma.

Radium-223 Plus Sipuleucel-T Yields Mixed Results in mCRPC

February 14th 2020

Combination therapy with radium-223 and sipuleucel-T yielded conflicting results in patients with metastatic castration-resistant prostate cancer.

Rush Named National Center of Excellence for Pancreatic Cancer

February 14th 2020

Rush is the only Illinois hospital to receive this National Pancreatic Foundation designation.

ACCC Quality Improvement Workshops Address the Need for Improved Chronic Lymphocytic Leukemia Care

February 5th 2020

The Association of Community Cancer Centers is pleased to announce that its Multidisciplinary Chronic Lymphocytic Leukemia Care education project is conducting a series of quality improvement workshops to promote the optimal care and management of patients diagnosed with chronic lymphocytic leukemia.

New Chapter Opens in Bladder Cancer Treatment

February 5th 2020

For years, the treatment landscape for bladder cancer was defined by lackluster consistency: There were no advances. However, the drought ended with the introduction of immune checkpoint blockade, according to Charles G. Drake, MD, PhD.